Advertisement
Organisation › Details
Sofinnova Partners SAS
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. *
Start | 1997-08-25 established | |
Group | Sofinnova (Group) | |
Industry | venture capital | |
Industry 2 | LIFE SCIENCES | |
Person | Papiernik, Antoine (Sofinnova Partners 201703 Managing Partner + Chairman joined 1997) | |
Person 2 | Lucquin, Denis (Sofinnova Partners 201509 Managing Partner + Chairman) | |
Region | Paris | |
Country | France | |
Street | 7–11 Boulevard Haussmann | |
City | 75009 Paris | |
Tel | +33-1-7623-4100 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2020-04-22) |
Currency | EUR | |
Annual sales | 2,500,000,000 (funds, managed (2023) 2023-12-13) | |
* Document for »About Section«: Sofinnova Partners. (12/13/23). "Press Release: Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups". Paris. | ||
Record changed: 2024-09-12 |
Advertisement
More documents for Sofinnova (Group)
- [1] Genespire S.r.l.. (9/25/24). "Press Release: Genespire Raises €46.6 Million (~$52 Million) in a Series B Round to Advance Its First Pediatric in-vivo Gene Therapy into the Clinic". Milan....
- [2] Novameat Tech SL. (9/12/24). "Press Release: Novameat Raises €17.4M Oversubscribed Series A Round Led by Sofinnova Partners and Forbion". Barcelona....
- [3] Sofinnova Partners. (9/10/24). "Press Release: Sofinnova Partners Appoints Karl Naegler as Partner". Paris....
- [4] Deepc GmbH. (7/24/24). "Press Release: Deepc Closes Series A Extension to Accelerate Global Deployment of Healthcare AI, Bringing Total Funding to $30m". Munich....
- [5] Endoron Medical Ltd.. (7/9/24). "Press Release: Endoron Medical Raises $10 Million in Series A Funding Led by Sofinnova Partners to Accelerate the Validation of Its AAA EndoStapling Solution Aortoseal". Tel Aviv....
- [6] Marea Therapeutics. (6/18/24). "Press Release: Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases". South San Francisco, CA....
- [7] Cure51 SAS. (3/20/24). "Press Release: Cure51 Raises a €15 Million Seed Round to Harness the Natural Power of Cancer Survivors to Develop First-in-Class Treatments and Transform Cancer into a Curable Disease". Paris....
- [8] Bioptimus SAS. (2/20/24). "Press Release: Ex-Google DeepMind and Owkin Scientists Team up to Create Bioptimus to Build the First Universal AI Foundation Model for Biology"....
- [9] GenSight Biologics S.A.. (2/8/24). "Press Release: GenSight Biologics Announces Completion of a €5 million capital Increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital". Paris....
- [10] Disco Pharmaceuticals GmbH. (1/16/24). "Press Release: Disco Pharmaceuticals Launches as the Surfaceome Company with EUR 20 Million in Seed Financing". Cologne & Zurich....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top